Semaglutide, the active ingredient in popular weight loss medications Ozempic and Wegovy, appears to pump the brakes on biological aging in human cells, according to new clinical research that opens unexpected doors for drugs already known to improve heart health and blood sugar control.
A randomized, placebo-controlled study published in Nature Communications found that people receiving semaglutide showed slower aging across multiple molecular markers tied to inflammation and the health of critical organs including the brain, heart, kidneys, and liver. The research marks the first time scientists have gathered solid evidence in humans that this class of drug may actually influence the aging process itself.
Researchers at UC San Diego examined data from 108 adults with HIV-associated lipohypertrophy, a condition marked by excess fat accumulation around the abdomen. Half received weekly semaglutide injections over the study period while the other half got placebo shots. To measure biological age, scientists used epigenetic clocks, tools that estimate how fast cells are aging by measuring DNA methylation patterns, the chemical tags that control how genes turn on and off without altering the DNA sequence itself.
Those treated with semaglutide showed a 9% slower pace of biological aging based on one epigenetic clock measurement, and significant slowing of biological processes linked to age-related disease and mortality risk on another. The differences between treatment and placebo groups were substantial enough to suggest the drug was actively intervening in aging mechanisms, not just producing minor shifts.
The mechanism behind this effect may involve semaglutide's ability to reduce inflammation and trim visceral fat, the dangerous deep belly fat wrapped around organs. This class of medication also eliminates ectopic fat that accumulates in places where it shouldn't exist. Both inflammation and excess fat have long been identified as accelerators of aging throughout the body, so their reduction could explain why the drug appeared to slow multiple aging clocks simultaneously.
Michael Corley, the study's lead author and an associate professor at the UC San Diego School of Medicine, emphasized that the findings extend beyond HIV treatment. People with HIV often experience accelerated aging even when the virus is controlled with modern drugs, making this population ideal for spotting interventions that could help the general population too. The biological processes examined in HIV are central to aging in everyone, he explained.
A second pilot study published in npj Aging reinforced these findings. Looking at semaglutide treatment in people with fatty liver disease, researchers found that 42% showed slower biological aging over 24 weeks, while nearly half showed longer telomeres, the protective caps at chromosome ends. Those with longer telomeres also tended to walk faster after treatment, suggesting real improvements in physical function.
Scientists are careful to clarify what their findings do not show. Semaglutide is not an anti-aging drug and does not reverse aging or make people younger. Rather, it appears to slow some of the molecular processes linked to aging. Corley noted that the field has an opportunity to test whether other drugs in the GLP-1 class produce different effects on aging and to identify which patients might benefit most.
Larger trials will be needed to confirm results, determine how long benefits persist, and figure out optimal treatment schedules for both people with HIV and broader populations. Researchers are also exploring whether combining semaglutide with diet, exercise, and quality sleep could amplify effects on aging.
Looking further ahead, UC San Diego's Stein Institute for Research on Aging wants to develop personalized aging dashboards based on epigenetic clocks, helping doctors monitor biological aging more precisely and design individual treatments targeting the root causes of age-related disease.
Author Jessica Williams: "These results suggest GLP-1 drugs may do far more than shrink waistlines, but calling them fountain-of-youth pills would be getting ahead of the science."
Comments